Electronic Health Records Ongoing Focus Of DOJ And HHS Enforcement
Since the eClinicalWorks settlement in 2017, the DOJ and HHS have focused on electronic health record vendors.
RELEASE: Fraud By The Numbers in 2022
As part of an ongoing effort to understand the impact of fraud, Taxpayers Against Fraud today released a new report on "Fraud By The Numbers in 2022."
What Does Fraud in the Medicare Advantage Space Mean for the Reverse False Claims Provision?
As the percentage of Medicare and Medicaid beneficiaries in managed care increases, there is a risk that fraudsters will misrepresent Medical Loss Ratios to the government.
Open Enrollment for Medicare Advantage Plans is Not Open Season for Fraud
The Department of Justice and whistleblowers have pursued False Claims Act cases against at least half of the top ten Medicare Part C providers.
A Tradition of Fraud Persists in New Types of Medicare Delivery Models
Unscrupulous medical providers, hospitals, and drug manufacturers, can and do defraud Medicare Advantage plans in the same ways they defraud “traditional” Medicare.
How the Inflation Reduction Act’s Medicare Provisions Will Combat Drug Pricing Fraud
If the IRA’s new Medicare provisions had been in place when the case against Eli Lilly was filed in 2014, many more taxpayer funds may have been recovered.
One Year’s Tax Revenue is Another Year’s Purchases of Drugs and Biologics
Nearly 70 percent of U.S. adults aged 40-79 used at least one prescription drug in 2019. In this blog, we explore the prevalence of fraud in the pharmaceutical industry.
Medical Devices Present Opportunities for Fraud, but Whistleblowers Are Fighting Back
In a single year, Medicare paid $13.5 billion for durable and single-use medical equipment, creating a big target for fraud.
Paycheck Protection Program Fraud: All Cannot Be Forgiven
Estimates say more money has been lost through this program than thirty four years of False Claims Act Litigation has recovered.
Private Equity Investment in Healthcare is Skyrocketing; Grandma Should Be Scared
Between 2010 and 2019, private equity deals in healthcare nearly tripled in value—from $43 billion to $124 billion—totaling $750 billion over the last decade.
